The drug, lecanemab was recently tested on patients with early Alzheimer.
About:
Lecanemab, is jointly developed by pharma companies Biogen and Eisai.
Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta amyloid, the protein deposition that is seen in patients with Alzheimer’s disease, and disrupts cells function.
Alzheimer’s disease
It is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. It involves parts of the brain that control thought, memory, and language.
It can seriously affect a person’s ability to carry out daily activities.
India’s scenario:
In India, only 1 in 10 peoplewith dementia receive any diagnosis, treatment or care for the disease, according to the World Alzheimer’s Report, 2021.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
